- AU$14.01m
- AU$11.04m
- AU$0.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.06 | ||
| Price to Tang. Book | 6.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 38.45 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -158.93% | ||
| Return on Equity | -317.64% | ||
| Operating Margin | -1496.28% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.06 | 0.12 | 0.32 | 0.61 | 0.36 | n/a | n/a | 11.74% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hera Med Ltd is an Israel-based company that develops pregnancy monitoring solutions for home and professional use. It offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The Company also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.
Directors
- Ronald Weinberger NEC
- David Groberman CEO
- Sivan Sadan CFO (48)
- Tal Slonim COO
- Jonathan Hart SEC
- Doron Birger NED (70)
- David Hinton NED
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 5th, 2011
- Public Since
- December 12th, 2018
- No. of Shareholders
- 1,245
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 875,602,742
- Address
- 4 Hazoran St., Pob 8576, NETANYA, 4250604
- Web
- https://www.hera-med.com/
- Phone
- Auditors
- BDO Audit (WA) PTY LTD
Upcoming Events for HMD
Hera Med Ltd Annual Shareholders Meeting
Similar to HMD
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the Hera Med share price?
As of Today at 21:04 UTC, shares in Hera Med are trading at AU$0.02. This share price information is delayed by 15 minutes.
How has the Hera Med share price performed this year?
Shares in Hera Med last closed at AU$0.02 and the price had moved by -8.57% over the past 365 days. In terms of relative price strength the Hera Med share price has underperformed the ASX All Ordinaries Index by -11.88% over the past year.
What are the analyst and broker recommendations for Hera Med?
There is no consensus recommendation for this security.
Find out moreWhat is the Hera Med dividend yield?
Hera Med does not currently pay a dividend.
Does Hera Med pay a dividend?
Hera Med does not currently pay a dividend.
When does Hera Med next pay dividends?
Hera Med does not currently pay a dividend.
How do I buy Hera Med shares?
To buy shares in Hera Med you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hera Med?
As of the previous close price of AU$0.02, shares in Hera Med had a market capitalisation of AU$14.01m.
Where are Hera Med shares listed?
Here are the trading details for Hera Med:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: HMD
What kind of share is Hera Med?
Based on an overall assessment of its quality, value and momentum Hera Med is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hera Med share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Hera Med share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hera Med. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -28.44%.
As of the last closing price of AU$0.02, shares in Hera Med were trading -19.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hera Med PE Ratio?
The Hera Med PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hera Med?
Hera Med's management team is headed by:
- Ronald Weinberger - NEC
- David Groberman - CEO
- Sivan Sadan - CFO
- Tal Slonim - COO
- Jonathan Hart - SEC
- Doron Birger - NED
- David Hinton - NED